Ghryvelin

Consilient Health announces that it has sold the exclusive rights and license that it holds from Aeterna Zentaris to commercialise Ghryvelin (macimorelin) in the EEA and UK for the diagnosis of Adult Growth Hormone Deficiency (AGHD) to Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines.